CD4 and neoplasm: Kristensen et al. found that the maximum [89Zr]-DFO-CD4 tumor-to-heart ratio could be used to stratify syngeneic mouse models, including 4T1, according to therapeutic response to Sym021, a humanized PD-1 antibody cross-reactive with mouse PD-1 [43].